ES2193256T3 - Aril pirroles 2-sustituidos, composiciones que contienen tales compuestos y procedimientos de uso. - Google Patents

Aril pirroles 2-sustituidos, composiciones que contienen tales compuestos y procedimientos de uso.

Info

Publication number
ES2193256T3
ES2193256T3 ES96928097T ES96928097T ES2193256T3 ES 2193256 T3 ES2193256 T3 ES 2193256T3 ES 96928097 T ES96928097 T ES 96928097T ES 96928097 T ES96928097 T ES 96928097T ES 2193256 T3 ES2193256 T3 ES 2193256T3
Authority
ES
Spain
Prior art keywords
compounds
compositions containing
pirroles
aril
substitutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96928097T
Other languages
English (en)
Inventor
Laszlo Stephen E De
Nathan B Mantlo
Gerald S Ponticello
Harold G Selnick
Nigel J Liverton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9607254.1A external-priority patent/GB9607254D0/en
Priority claimed from GBGB9609264.8A external-priority patent/GB9609264D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2193256T3 publication Critical patent/ES2193256T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A ARIL PIRROLES 2 SUSTITUIDOS, ASI COMO A COMPOSICIONES QUE CONTIENEN ESTOS COMPUESTOS Y METODOS DE TRATAMIENTO. POR ENFERMEDADES MEDIADAS POR CITOQUINAS SE ENTIENDEN ENFERMEDADES O ESTADOS EN QUE TIENE LUGAR UNA PRODUCCION O ACTIVIDAD EXCESIVA O NO REGULADA DE UNA O MAS CITOQUINAS. LA INTERLEUQUINA - 1 (IL - 1), INTERLEUQUINA 6 (IL 6), INTERLEUQUINA - 8 (IL - 8) Y EL FACTOR DE NECROSIS TUMORAL (TNF) SON CITOQUINAS QUE ESTAN IMPLICADAS.
ES96928097T 1995-08-10 1996-08-08 Aril pirroles 2-sustituidos, composiciones que contienen tales compuestos y procedimientos de uso. Expired - Lifetime ES2193256T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US209395P 1995-08-10 1995-08-10
US1418196P 1996-03-26 1996-03-26
GBGB9607254.1A GB9607254D0 (en) 1996-04-04 1996-04-04 2-Substituted aryl pyrroles, compositions containing such compounds and methods of use
GBGB9609264.8A GB9609264D0 (en) 1996-05-02 1996-05-02 2-Substituted aryl pyrroles,compositions containing such compounds and methods of use

Publications (1)

Publication Number Publication Date
ES2193256T3 true ES2193256T3 (es) 2003-11-01

Family

ID=27451431

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96928097T Expired - Lifetime ES2193256T3 (es) 1995-08-10 1996-08-08 Aril pirroles 2-sustituidos, composiciones que contienen tales compuestos y procedimientos de uso.

Country Status (8)

Country Link
EP (1) EP0863757B1 (es)
JP (1) JP3294616B2 (es)
AT (1) ATE235239T1 (es)
AU (1) AU705082B2 (es)
CA (1) CA2228136A1 (es)
DE (1) DE69627006T2 (es)
ES (1) ES2193256T3 (es)
WO (1) WO1997005877A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
EP0912548A1 (en) 1996-07-11 1999-05-06 Pfizer Inc. Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
DE69835518T2 (de) 1997-06-12 2007-08-09 Aventis Pharma Ltd., West Malling Imidazolyl-cyclische acetale
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
AU1924699A (en) 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
IL136711A0 (en) * 1997-12-19 2001-06-14 Amgen Inc Substituted pyridine and pyridazine compounds and their pharmaceutical use
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6649617B1 (en) 1998-10-07 2003-11-18 Smithkline Beecham Corporation Treatment for stroke management
DE69914357T2 (de) 1998-11-04 2004-11-11 Smithkline Beecham Corp. Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
AU2871900A (en) * 1999-02-04 2000-08-25 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
CO5170501A1 (es) * 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
WO2000066124A1 (fr) * 1999-04-28 2000-11-09 Sankyo Company, Limited Agents preventifs ou inhibiteurs destines a une hepatopathie
CA2374559A1 (en) * 1999-05-14 2000-11-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
IL137365A0 (en) * 1999-07-21 2001-07-24 Sankyo Co Heteroaryl-substituted pyrrole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
WO2001034149A1 (en) * 1999-11-12 2001-05-17 Merck & Co., Inc. Diaryl piperidyl pyrrole derivatives as antiprotozoal agents
JP2003514900A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
EP1233950B1 (en) 1999-11-23 2005-10-05 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
RU2198170C2 (ru) * 1999-12-27 2003-02-10 Санкио Компани, Лимитед Производные пиррола, фармацевтические композиции на их основе и способ лечения
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
WO2002057254A1 (en) * 2001-01-18 2002-07-25 Sankyo Company, Limited Compositions for prevention or treatment of hepatopathy
WO2002057255A1 (en) * 2001-01-22 2002-07-25 Sankyo Company, Limited 4- or 5-substituted pyrrole derivatives
ATE377598T1 (de) * 2001-01-22 2007-11-15 Sankyo Co Durch bicyclische aminogruppen substituierte verbindungen
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
WO2002094267A1 (en) * 2001-05-24 2002-11-28 Sankyo Company, Limited Pharmaceutical composition for prevention or treatment of arthritis
EP2152271B1 (en) 2007-06-08 2015-10-21 Janssen Pharmaceutica, N.V. Piperidine/piperazine derivatives
JP5464709B2 (ja) 2007-06-08 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン／ピペラジン誘導体
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
ES2536406T3 (es) 2007-06-08 2015-05-25 Janssen Pharmaceutica, N.V. Derivados de piperidina/piperazina
PE20100083A1 (es) 2008-06-05 2010-02-17 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
CA2803880C (en) * 2010-06-28 2018-09-25 President And Fellows Of Harvard College Compounds for the inhibition of cellular proliferation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735958A (en) 1986-12-22 1988-04-05 Warner-Lambert Company Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
EP0300688A1 (en) * 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
WO1993019067A1 (en) 1991-09-12 1993-09-30 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine derivatives as angiotensin ii antagonists
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
GB9202633D0 (en) 1992-02-07 1992-03-25 Fujisawa Pharmaceutical Co Heterocyclic derivatives
JPH07507271A (ja) 1992-03-03 1995-08-10 藤沢薬品工業株式会社 アンジオテンシン１１拮抗剤としてのベンズイミダゾール誘導体
WO1996017841A1 (en) * 1994-12-06 1996-06-13 Nippon Soda Co., Ltd. Pyridylpyrrole compounds, process for production, and agrohorticultural bactericide

Also Published As

Publication number Publication date
CA2228136A1 (en) 1997-02-20
AU705082B2 (en) 1999-05-13
JP3294616B2 (ja) 2002-06-24
DE69627006T2 (de) 2004-01-15
EP0863757A4 (es) 1998-09-16
ATE235239T1 (de) 2003-04-15
AU6768996A (en) 1997-03-05
DE69627006D1 (de) 2003-04-30
EP0863757B1 (en) 2003-03-26
JPH11510510A (ja) 1999-09-14
EP0863757A1 (en) 1998-09-16
WO1997005877A1 (en) 1997-02-20

Similar Documents

Publication Publication Date Title
ES2193256T3 (es) Aril pirroles 2-sustituidos, composiciones que contienen tales compuestos y procedimientos de uso.
NO996120D0 (no) Imidazolyl-cykliske acetaler
BR9506741A (pt) Aplicação de anticorpos anti-tnf como medicamentos para o tratamento de doenças que apresentam elevados niveis de interleuquin-5 no soro
NO20023008L (no) Cykliske AMP-spesifikke fosfodiesterase-inhibitorer
FI935585A0 (fi) Pyrrolopyrimidiner
NO20054959D0 (no) Fremgangsmater for behandling av interleukin-6 relaterte sykdommer
DK1119362T3 (da) Anvendelse af tetracyclinderivater til forögelse af interleukin-10-produktion
DE60007897D1 (de) 3-thiazol-4-yl-pyrrolidinderivate als amp-spezifische phosphodiesterase-inhibitoren
BR9811805A (pt) Derivados quinazolina substituìda e seu uso como inibidores de quinase tirosina
AR002267A1 (es) Compuestos de imidazol utiles para el tratamiento de patologias mediadas por citoquinas; composicion farmaceutica que los contiene; proceso para preparar dichos compuestos; uso del mismo para preparar dichas composiciones; compuestos intermediarios y procesos para su preparacion.
BRPI0410905A (pt) inibidores de p-38
DE69636308D1 (de) Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
DE69934094D1 (de) N-hydroxyformamid-derivate
ATE149353T1 (de) Guluronsäurepolymere und ihre verwendung zur hemmung von cytokinen
YU84102A (sh) Nova dibenzoazulen jedinjenja kao inhibitori faktora nekroze tumora
DK0572537T3 (da) Cytokinnhibitorer
HRP20030215B1 (en) Chemokine mutants in the tratment of multiple sclerosis
DE60018470D1 (de) Cyclische amp spezifische phosphodiesterase inhibitoren
ATE429434T1 (de) 6,7-dihydro-5h-pyrazolo 1,2-a pyrazol-1-one zur kontrolle von entzündungsfördernden cytokinen
CA2487331A1 (en) Anti-inflammatory compositions and methods of use
NO972906D0 (no) 4,4-(Disubstituerte)cykloheksan-1-ol-monomerer og beslektede forbindelser
BR9812489A (pt) Uso de 6,7-substituìdas-2-aminotetralinas adequadas para a preparação de uma composição farmacêutica para o tratamento terapêutico de patologias inflamatórias e/ou autoimunes
MX9704740A (es) Monomeros de 3,3-(disustituido)ciclohexan-1-ol y compuestos relacionados.